Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06186219 · ClinicalTrials.gov registry record · Phase 1
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT06186219 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 2 participants.
The verdict
NCT06186219, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-Pegloticase.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06186219
The ClinicalTrials.gov registry entry for NCT06186219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT06186219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06186219 about?
NCT06186219 is a clinical study titled "Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout". This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-...
What is the current status of trial NCT06186219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2024-04-10. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT06186219?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT06186219?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.